Abstracts tagged "infliximab and spondylarthritis"

Abstract Number: 721 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Switching from Originator to CT-P13 Infliximab Biosimilar in Patients Affected By Spondyloarthritis. a 6-Month Observational Study
Alberto Batticciotto^1,2, Marco Antivalle², Francesca Li Gobbi³, Simone Parisi⁴, Rossella Talotta², Valentina Varisco², Maurizio Benucci³, Enrico Fusaro⁴ and Piercarlo Sarzi-Puttini¹, ¹Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy, ²Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy, ³Rheumatology Unit, Ospedale S. Giovanni di Dio, Florence, Florence, Italy, ⁴Department of Rheumatology, University Hospital Città Della Salute e della Scienza di Torino, Turin, Italy
Background/Purpose: Biosimilar infliximab (INX) was recently approved by the European Medicine Agency based on comparable pharmacokinetics, safety and efficacy profile to innovator INX for the…
Abstract Number: 2881 • 2015 ACR/ARHP Annual Meeting
Infliximab in Spondyloarthritis Patients: Utility of Drug Level Monitoring
Claudia Deaconu¹, Diana Mazilu², Laura Grosanu², Ioana Saulescu², Andreea Borangiu², Cecilia Gainaru³, Cosmin Constantinescu², Violeta Bojinca², Violeta Vlad¹, Andra Balanescu², Denisa Predeteanu², Ruxandra Ionescu² and Daniela Opris², ¹Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ²University of Medicine and Pharmacy “Carol Davila”, Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ³"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
Background/Purpose: Spondyloarthritides, a heterogeneous group of chronic, inflammatory disorders with overlapping organ and joint targeting, share the same therapeutic approach in regard to biological therapy.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].